Health Technology Innovation Platform
The IHE has recently established the Health Technology Innovation Platform (HTIP), a three (3) year collaboration that includes organizations from both the public and private sectors, spanning different perspectives including regulatory, health technology assessment, payer, and innovative pharmaceutical industry. The three (3) year program of work is supported through funding from Boehringer Ingelheim, GlaxoSmithKline, Roche Canada, Takeda Canada, Astra Zeneca Canada and Novartis Pharmaceuticals Canada Inc. with a Steering Committee that includes these organizations as well as provincial drug plans (AB, BC, ON), Health Canada, and the Canadian Agency for Drugs and Technologies in Health (CADTH).
The mission of the HTIP is to:
- improve ability to assess value for money for purchasers of health technology,
- operationalize the development of a pro-innovation ecosystem across Canada,
- strengthen constructive policy dialogue between technology developers and all levels of government and healthcare payers,
- create certainty and/ or reduce the risk, to both payers and developers, inherent in value demonstration processes.
Three (3) Strategic Priorities have been identified by the HTIP Collaborators:
- RWE-enabled conditional licensing and adoption of innovation - foster advances in the production and utilization of real world evidence (RWE) to support improved pharmaceutical lifecycle health technology management (HTM), including enabling earlier adoption of technology with continuous assessment of safety, effectiveness, and value.
- Enabling risk management frameworks and agreements - development of risk and performance management frameworks that effectively address the uncertainty that is inherent in the prompt adoption of innovation, and enable value-based investment and re-investment decision-making.
- Innovative funding models - development of innovative pharmaceutical reimbursement funding options, utilizing novel decision frameworks and model gap analyses, in order to facilitate adoption of new technologies for which current options are not adequate.
Work is currently underway to develop tools and resources around each priority, and will be shared in structured manner once finalized.